Literature DB >> 23580583

In vitro interaction between cefepime and amoxicillin-clavulanate against extended-spectrum β-lactamase-producing Escherichia coli.

Edouard Bingen, Philippe Bidet, Camille D'humières, Elsa Sobral, Patricia Mariani-Kurkdjian, Robert Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23580583      PMCID： PMC3632925          DOI： 10.1128/AAC.01839-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3.

Authors:  Laurent Poirel; Marek Gniadkowski; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.

Authors:  Edouard Bingen; Philippe Bidet; André Birgy; Elsa Sobral; Patricia Mariani; Robert Cohen
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

3.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

4.  Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae.

Authors:  Hélène Garrec; Laurence Drieux-Rouzet; Jean-Louis Golmard; Vincent Jarlier; Jérôme Robert
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

5.  Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Authors:  Teena Chopra; Dror Marchaim; Jennifer Veltman; Paul Johnson; Jing J Zhao; Ryan Tansek; Dania Hatahet; Khawar Chaudhry; Jason M Pogue; Hiro Rahbar; Ting-Yi Chen; Thientu Truong; Victor Rodriguez; Joseph Ellsworth; Luigino Bernabela; Ashish Bhargava; Adnan Yousuf; George Alangaden; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

6.  Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  B Balke; M Hogardt; S Schmoldt; L Hoy; H Weissbrodt; S Häussler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

7.  Clavulanate and beta-lactamase induction.

Authors:  D M Livermore; M Akova; P J Wu; Y J Yang
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

8.  Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Authors:  K S Thomson; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 9.  Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.

Authors:  D M Livermore; R Hope; S Mushtaq; M Warner
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

10.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.